首页> 美国卫生研究院文献>Cancers >Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers Two Sides of the Same Coin
【2h】

Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers Two Sides of the Same Coin

机译:优化Loco区域管理的寡核差距结直肠癌:技术方面和生物标志物同一硬币的两侧

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The treatments for patients with oligometastatic colorectal carcinoma are rapidly evolving. The present review focuses on the role of minimally invasive techniques since they can now be used as an alternative to surgical management in selected cases in association with systemic therapies according to ESMO and NCCN guidelines. In recent years, biomarkers (both at molecular and imaging level) have emerged as a relevant and potential criteria for treatment strategy decision and will be crucial in the future for patients selection. Tumor molecular profile impacts on local outcome of image guide ablation as well as metabolic imaging which predicts the outcome of both percutaneous and trans-arterial treatments. Oncologists should be aware of advantages and disadvantages of those treatments options as well as the potential role of molecular profile for a better patient selection.
机译:寡粒度结直肠癌患者的治疗迅速发展。本综述重点介绍了微创技术的作用,因为它们现在可以用作根据ESMO和NCCN指南与系统疗法结合的选定病例中的手术管理的替代方案。近年来,生物标志物(分子和成像水平)被出现为治疗战略决策的相关和潜在标准,对患者选择的未来将是至关重要的。肿瘤分子曲线对图像引导烧蚀的局部结果的影响以及代谢成像,其预测经皮和跨动脉治疗的结果。肿瘤科医生应该了解这些治疗方案的优缺点以及分子谱的潜在作用,以便更好的患者选择。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号